http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2386759-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3873abaff397acbfffa1595a12cfef41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2613944636ab2fdf3f83ef2d4b304f0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 |
| filingDate | 2002-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cd5ab1974d48f1c69e1dccfe50b3adc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_342084a45dadf98de99dc34b38d0e113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_939051fb1334e4dd2712dc9b2b51ef38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0994a404d697ac828c58fb018ede244 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61b0bc93fc6c29c762ea54af24bfffc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b51dc08ed8e481e468fde850bcb75c7 |
| publicationDate | 2003-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2386759-A1 |
| titleOfInvention | Therapeutic uses of peroxometallic compounds |
| abstract | The present invention relates to the use of peroxometallic compounds, such peroxovanadium compounds, to prevent angiogenesis, restenosis and the production of endothelins, as immunomodulators and as antitumorigenic agents. Peroxometallic compounds are preferred since they are more potent, and less toxic, than their "oxo" counterparts, as exemplified by specific peroxovanadium compounds. Anti-angiogenic activity was verified in vitro against human umbilical vascular endothelial cells (HUVECs) as well as ex ovo using the chicken chorioallantoic assay membrane and in the rat aortic ring model and a Matrigel assay in vivo. Peroxovanadium compounds also decrease basal levels and inhibit the increase in plasma endothelins occurring following insulin induction in rats. It is proposed that peroxovanadium compounds are therapeutically-active anti-angiogenics and useful in preventing vascular restenosis by acting, inter alia, by inhibiting one or several protein tyrosine phosphatases (PTPs) involved in the proliferation, differentiation and migration of cells or the secretion of peptides (such endothelins and immunomodulators), or both. These compounds have also been found to be suitable as antitumorigenic agents in the treatment of cancer, such as breast cancer and prostate cancer. |
| priorityDate | 2002-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 589.